Tag archief: English Only

Boehringer Ingelheim Partners with Enleofen to Develop First-in-Class Anti-IL-11 Therapies for a Range of Fibrotic Diseases

Acquisition of worldwide exclusive rights adds extensive anti-IL-11 platform to Boehringer Ingelheim pipeline portfolio Boehringer Ingelheim aims to develop therapies for multiple fibrotic human disorders,...

F-star Therapeutics Appoints Dr. Edward Benz and Mr. Geoff Race to Board of Directors

CAMBRIDGE, England & CAMBRIDGE, Mass.–(BUSINESS WIRE)– F-star Therapeutics (“F-star”), a clinical-stage biopharmaceutical company focused on transforming the lives of patients with cancer through the development...

ZEDRA to acquire BNP Paribas Singapore Trust Corporation Limited

SINGAPORE–(BUSINESS WIRE)– The rapidly expanding ZEDRA group has announced another key acquisition, this time in Singapore. The Group will acquire BNP Paribas Singapore Trust Corporation...

RoboSense Announces World ’s First Public Road Test of Vehicle Equipped With Smart Lidar Sensor at CES 2020

RoboSense Smart LiDAR Car Features World’s First MEMS Smart LiDAR with Built-in AI Algorithm Perception Results Road Tests Running Daily Outside LVCC at CES 2020...

Elliott Publishes Letter on Capgemini’s Offer for Altran

Elliott believes Offer price is now even less adequate, and shares its rationale for its current intention to not tender Full materials available at www.FairValueforAltran.com...

GSMA Intelligence: US and European Consumers Cautious on Move to 5G Devices, China and Korea Set to Lead Early Adoption

Mixed Picture on 5G Impact on Smartphone Upgrades, Smart Speaker Momentum Continues LAS VEGAS–(BUSINESS WIRE)– The smartphone will remain the dominant consumer device into the...

ENHERTU® Now Available in U.S. for HER2 Positive Unresectable or Metastatic Breast Cancer Following Two or More Prior Anti-HER2-Based Regimens

TOKYO & BASKING RIDGE, N.J.–(BUSINESS WIRE)– Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that ENHERTU® (fam-trastuzumab deruxtecan-nxki), a HER2 directed antibody drug conjugate,...

Berkshire Hathaway Specialty Insurance Appoints Hilary Browne Country Manager, Ireland & Head of Casualty, UK & Europe

BOSTON & LONDON & DUBLIN–(BUSINESS WIRE)– Berkshire Hathaway Specialty Insurance (BHSI) today announced that it has named Hilary Browne to the dual role of Country...

Traxens Opens Offices in China to Meet Needs of Growing Asian Supply Chain Market

First office outside of France will be headed by Mr. Vincent Gu, appointed as managing director ASPAC, to help company set foot in booming market...

Ipsen: Dysport® (clostridium botulinum type A toxin-haemagglutinin complex) now approved in the UK for symptomatic treatment of upper limb spasticity in children with cerebral palsy

– Making it the first and only botulinum toxin in the UK to be approved for the treatment of pediatric spasticity in both upper and...

RoboSense 125-Laser Beam Solid-State LiDAR: RS-LiDAR-M1 Is Officially on Sales Priced At $1,898

World’s First Smart LiDAR Sensor Will Be Demonstrated at CES2020 with On-Vehicle Public Road Test SHENZHEN, China–(BUSINESS WIRE)– RoboSense, the world’s leading autonomous driving LiDAR...

Gilead and Eisai Enter Into Agreement in Japan for the Co-Promotion of the Investigational Rheumatoid Arthritis Therapy Filgotinib, Pending Regulatory Approval

— Agreement Extends to Additional Potential Indications for Filgotinib, Including Ulcerative Colitis, Crohn’s Disease and Psoriatic Arthritis — FOSTER CITY, Calif. & TOKYO–(BUSINESS WIRE)– Gilead...

Gilead Sciences to Present at the 38th Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2020

Webcast Available Through Gilead Corporate Website FOSTER CITY, Calif.–(BUSINESS WIRE)– Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Daniel O’Day, Gilead’s Chairman and Chief Executive...

ViiV Healthcare receives complete response letter from US FDA for use of investigational cabotegravir and rilpivirine long-acting regimen in the treatment of HIV

LONDON–(BUSINESS WIRE)– ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, received a complete response...

ENHERTU® Approved in the U.S. for HER2 Positive Unresectable or Metastatic Breast Cancer Following Two or More Prior Anti-HER2-Based Regimens

Accelerated Approval of Daiichi Sankyo and AstraZeneca’s ENHERTU® (fam-trastuzumab deruxtecan-nxki) based on the pivotal DESTINY-Breast01 trial that showed clinically meaningful and durable responses TOKYO &...